The meeting of the American Society of Oncology focused on optimizing immunotherapy and other advanced treatments for improving survival

Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard therapies cut the risk of disease progression or death by half, a finding that could be practice changing,

AstraZeneca Plc’s experimental breast cancer pill delayed disease progression by over six months, according to data from a new study that is likely to capture investors’ attention.